CYTK logo

CYTK
Cytokinetics Inc

4,553
Mkt Cap
$8.22B
Volume
1.5M
52W High
$70.98
52W Low
$29.31
PE Ratio
-10.21
CYTK Fundamentals
Price
$66.71
Prev Close
$65.42
Open
$66.30
50D MA
$63.99
Beta
0.89
Avg. Volume
2.1M
EPS (Annual)
-$6.54
P/B
-12.43
Rev/Employee
$130,815.75
$8,030.25
Loading...
Loading...
News
all
press releases
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 7,500 Shares of Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert Blum sold 7,500 shares of the business's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $65.38, for a total transaction of $490,350.00. Following the sale, the chief executive officer...
MarketBeat·3d ago
News Placeholder
Massachusetts Financial Services Co. MA Cuts Position in Cytokinetics, Incorporated $CYTK
Massachusetts Financial Services Co. MA lessened its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 34.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 327,202 shares...
MarketBeat·3d ago
News Placeholder
Andrew Callos Sells 7,449 Shares of Cytokinetics (NASDAQ:CYTK) Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 7,449 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $66.02, for a total transaction of $491,782.98. Following the completion of the sale, the executive vice...
MarketBeat·4d ago
News Placeholder
Cytokinetics (NASDAQ:CYTK) CEO Robert Blum Sells 7,500 Shares
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert Blum sold 7,500 shares of Cytokinetics stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $65.38, for a total transaction of $490,350.00. Following the transaction, the chief executive...
MarketBeat·4d ago
News Placeholder
Cytokinetics Highlights MYQORZO Launch Progress, Teases 2026 Phase 3 Readout at Needham Conference
Cytokinetics (NASDAQ:CYTK) executives outlined early commercialization efforts for MYQORZO and previewed several upcoming clinical and regulatory milestones during a fireside chat at Needham's 25th...
MarketBeat·6d ago
News Placeholder
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Wells Fargo & Company
Wells Fargo & Company assumed coverage on shares of Cytokinetics in a research note on Friday. They set an "overweight" rating and a $95.00 price objective on the stock...
MarketBeat·9d ago
News Placeholder
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 4,500 Shares
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 4,500 shares of Cytokinetics stock in a transaction on Tuesday, April 7th. The stock was sold at an average...
MarketBeat·11d ago
News Placeholder
Barclays Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price
Barclays boosted their price objective on Cytokinetics from $87.00 to $95.00 and gave the stock an "overweight" rating in a research note on Monday...
MarketBeat·13d ago
News Placeholder
Aberdeen Group plc Sells 444,771 Shares of Cytokinetics, Incorporated $CYTK
Aberdeen Group plc trimmed its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 47.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The...
MarketBeat·15d ago
<
1
2
...
>

Latest CYTK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.